Abstract
Quantitative structure-activity relationship studies on a series of selective inhibitors of thrombin and factor Xa were performed by using Associative Neural Network. To overcome the problem of overfitting due to descriptor selection, 5-fold cross-validation with variable selection in each step of the analysis was performed. The predictive ability of the models was tested through leave-one-out cross-validation, giving a Q2=0.74 - 0.87 for regression models. Predictions for the external evaluation sets obtained accuracies in the range of 0.71 - 0.82 for regressions. The proposed models can be potential tools for finding new drug candidates.
Keywords: Drug design, factor Xa, QSAR, Neural Networks, thrombin.
Current Computer-Aided Drug Design
Title:Prediction of Thrombin and Factor Xa Inhibitory Activity with Associative Neural Networks
Volume: 10 Issue: 3
Author(s): Vasyl Kovalishyn, Vsevolod Tanchuk, Iryna Kopernyk, Volodymyr Prokopenko and Larysa Metelytsia
Affiliation:
Keywords: Drug design, factor Xa, QSAR, Neural Networks, thrombin.
Abstract: Quantitative structure-activity relationship studies on a series of selective inhibitors of thrombin and factor Xa were performed by using Associative Neural Network. To overcome the problem of overfitting due to descriptor selection, 5-fold cross-validation with variable selection in each step of the analysis was performed. The predictive ability of the models was tested through leave-one-out cross-validation, giving a Q2=0.74 - 0.87 for regression models. Predictions for the external evaluation sets obtained accuracies in the range of 0.71 - 0.82 for regressions. The proposed models can be potential tools for finding new drug candidates.
Export Options
About this article
Cite this article as:
Kovalishyn Vasyl, Tanchuk Vsevolod, Kopernyk Iryna, Prokopenko Volodymyr and Metelytsia Larysa, Prediction of Thrombin and Factor Xa Inhibitory Activity with Associative Neural Networks, Current Computer-Aided Drug Design 2014; 10 (3) . https://dx.doi.org/10.2174/157340991003150302231419
DOI https://dx.doi.org/10.2174/157340991003150302231419 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review
Current Neuropharmacology The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Current Pharmaceutical Design Old Versus New Anticoagulants: Focus on Pharmacology
Recent Patents on Cardiovascular Drug Discovery Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?
Cardiovascular & Hematological Disorders-Drug Targets Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Proinflammatory Activities of Leptin in Non-Autoimmune Conditions
Inflammation & Allergy - Drug Targets (Discontinued) Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Perinatal Management of Fetal Tumors
Current Pediatric Reviews The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Novel Integrin-Specific Targets for Anti-Platelet Therapies
Current Pharmaceutical Design Local Drug Delivery to Inner Ear for Treatment of Hearing Loss
Current Drug Therapy The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Importance of Snake Venom Metalloproteinases in Cell Biology: Effects on Platelets,Inflammatory and Endothelial Cells
Current Pharmaceutical Design Changes of Expression of the Protein C Pathway Components in LPSInduced Endotoxemia–Implication for Sepsis
Cardiovascular & Hematological Disorders-Drug Targets Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis
Current Drug Targets Topical Antimicrobials for Burn Wound Infections
Recent Patents on Anti-Infective Drug Discovery Nitric Oxide and Disorders of the Erythrocyte: Emerging Roles and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets